CytomX earns $5 million milestone payment in Regeneron cancer drug collaboration
CTMX•CytomX Therapeutics achieved a preclinical milestone in its collaboration with Regeneron, triggering a $5 million payment.
CTMX•CytomX Therapeutics achieved a preclinical milestone in its collaboration with Regeneron, triggering a $5 million payment.
The milestone advances work toward clinical development of conditionally activated cancer therapies designed to limit activity outside tumors. The collaboration began in 2022 and expanded in June 2026, combining CytomX’s therapeutic masking technology with Regeneron’s bispecific antibody platform.